SCHEMBL2368629

SCHEMBL2368629

Cc1sc(N)cc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2B6 P20813 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
IKBKB O14920 1/20 0.40
TDO2 P48775 1/20 0.38
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
ESR2 Q92731 1/20 0.38
BACE1 P56817 1/20 0.38
KDM4E B2RXH2 4/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10493450 0.80 IKBKB (0.43) ALDH1A1IKBKBTDO2KDM4EMAPT
SCHEMBL2368789 0.80 PTGS2 (0.53) IKBKBTDO2KDM4EMAPTHPGD
SCHEMBL3423443 0.78 ALDH1A1 (0.44) ALDH1A1CYP2A6CYP2B6PDE4APDE4B
SCHEMBL5153317 0.78 TDO2 (0.45) ALDH1A1HSD17B10IKBKBTDO2SMARCA2
SCHEMBL1982822 0.77 TDO2 (0.50) ALDH1A1HSD17B10CYP2A6CYP2B6TDO2
SCHEMBL10205947 0.77 PLA2G10 (0.49) ALDH1A1CYP2A6CYP2B6ESR2BACE1
SCHEMBL15652195 0.76 BRD4 (0.42) ALDH1A1C1SRORCRORB
SCHEMBL11964997 0.75 CYP2A6 (0.41) ALDH1A1CYP2A6CYP2B6ESR2BACE1
SCHEMBL8071081 0.75 ALDH1A1 (0.38) ALDH1A1HSD17B10PDE4APDE4BPDE4C
SCHEMBL2616385 0.72 CYP2A6 (0.38) HSD17B10CYP2A6CYP2B6ESR2BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 ALDH1A1 247/4885HSD17B10 905/4885CYP2A6 391/4885
US-20090048258-A1 Amide Compound DLAT, DGAT1, DGAT2 ALDH1A1 435/4885HSD17B10 313/4885CYP2A6 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.